CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024

Stock Information for Cytodyn Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cytodyn Inc

CytoDyn Engages Leading CRO For Phase II Inflammation Trial
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
CytoDyn Announces Settlement with Amarex Clinical Research LLC
CytoDyn to Host Webcast to Provide Company Update
May 2024 Letter to Shareholders
CytoDyn Announces FDA Has Lifted Clinical Hold
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.